EphA2 overexpression was identified as required for overcoming sorafenib resistance in hepatocellular carcinoma cells: in fact, ligand mimicry in combination with sorafenib abated the resistance in vitro and in vivo by triggering EphA2 degradation [133]. Here, EPHA2 is linked to hepatocellular carcinoma.